Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

CAPTIVATE CorrelAtes of Protective immuniTy-driven Investigation of malaria VAccine combinaTion stratEgies

Coordinator
European Vaccine Initiative eV, Germany
Runs
1 November 2023 to 30 April 2028
Status
Running
EU funding
€8.7m
Total cost
€8.7m
Partners
9 organisations in 6 countries
Type
Research and Innovation Action
Grant agreement
101081028

What the project is doing

In the project's own words, from its summary on CORDIS.

Malaria remains a serious health concern worldwide, with P. falciparum considered one of the deadliest human parasites. Yet, the currently approved vaccine against malaria (RTS,S/AS01) offers limited protection due to challenges in vaccine development. Using current advances made in understanding immunity to address some of the existing challenges, this proposal aims to develop a more efficacious vaccine against P. falciparum by targeting multiple developmental stages (sporozoite, liver and blood-stage).

In this project, combinations of 1) highly promising whole parasite vaccination approach targeting the liver (late-arresting GAP), 2) RTS,S (provided by GSK) and 3) mRNA versions of clinically evaluated and partially protective blood stage vaccine candidates (Rh5, AMA1-DiCo [sporozoite and blood stage]) will be evaluated in preclinical and small-scale human trials to discern the optimal combination for further clinical investigations.

To inform a rational design of future vaccine candidates, CAPTIVATE will analyse the vaccine-induced immune response to acquire a full understanding of malaria protective immunity and develop an advanced immunology in-silico platform. While immunity to blood stage malaria is relatively well understood, the mechanisms of adaptive protective immunity for pre-erythrocytic malaria vaccine candidates are less well-established.

CAPTIVATE addresses this critical knowledge gap by combining state-of-the-art preclinical and clinical (CHMI) in vivo malaria vaccine efficacy models with an innovative in-silico platform comprising TCR/VDJ sequencing and artificial intelligence predictions, to identify such mechanisms. CAPTIVATE assembles a unique combination of European experts in their respective fields (malaria modelling in primates, clinical vaccine testing, in-silico modelling of immune responses, innovative omics approaches) in an integrated interdisciplinary approach aimed at bringing the next generation malaria vaccines to the clinic.

Topics

Who is involved

OrganisationCityCountryRole
European Vaccine Initiative eVHeidelbergGermanyCoordinator
University of New South WalesSydneyAustraliaAssociatedpartner
Immunewatch BVAntwerpenBelgiumParticipant
Quantoom BiosciencesNivellesBelgiumParticipant
Fyziologicky Ustav Akademie Ved Ceske Republiky Verejna Vyzkumna Instituce (vvi)Praha 4CzechiaParticipant
Deutsches Krebsforschungszentrum HeidelbergHeidelbergGermanyParticipant
Academisch Ziekenhuis LeidenLeidenNetherlandsParticipant
Stichting Biomedical Primate Research CenterRijswijk ZhNetherlandsParticipant
Nec Oncoimmunity ASOsloNorwayParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI